Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression.

Zydus Lifesciences on Wednesday said it has launched ANVIMO, a breakthrough medication for the prevention of Cytomegalovirus ...

Zydus Lifesciences introduces ANVIMO (Letermovir) for CMV prevention in transplant patients, offering a safer, ...